Udaan CEO Vaibhav Gupta outlines a clear path to IPO in 18–24 months, with 45% growth targets and a strong push in FMCG, ...

Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today ...

Estuary also recently secured additional financing related to the Escape project. This included closing the initial funding pursuant to a tax equity investment commitment by Morgan Stanley Renewables ...

Net income of $28.9 million on $154.5 million in revenue, compared to net income of $30.6 million on $189.0 million in revenue in Q2 2024 ...

Shares end little changed as miners offset banks. Gold miners rally on US jitters. Endeavour rallies after chair quits. Beach ...

As India sets its sights on a USD 35 trillion future by 2047, the real engine of growth will not just be factories or exports ...

Build muscle mass and keep growing stronger with CrazyBulk’s legal strength training supplements. Explore the best stacks for ...

Detailed price information for Dare Bioscience Inc (DARE-Q) from The Globe and Mail including charting and trades.

Consequently, the 12-pulse is extended to 48, resulting in an almost sinusoidal input current with a total harmonic distortion of 3.2% and an output current with a ripple rate of 2.3%, thus ...

Kennedy Jr. has spent a lot of his time as health secretary on the road. Late last month, he spoke at an event in Baton Rouge and lamented how Americans have gotten sicker and sicker over the years.

Clorox delivered a substantial beat on both revenue (GAAP) and adjusted EPS (non-GAAP) in Q4 FY2025, primarily due to a one-time boost from ERP-related shipments. Underlying consumer demand and ...